98%
921
2 minutes
20
Objective: This study aimed to share early- and mid-term results in patients with bicuspid aortic valve (BAV) disease who underwent tricuspidization with the Ozaki procedure. The data of 44 patients (32 males, 12 females; mean age: 51.47±15.18 years) diagnosed with BAV who underwent tricuspidization with the aortic valve neocuspidization technique between February 2019 and July 2024 were retrospectively analyzed.
Results: Additional surgical procedures were performed on 21 (47.72%) patients with BAV morphology. Echocardiographic measurements showed a significant reduction in preoperative peak and mean aortic valve pressures at one and 12 months. In patients who underwent simultaneous surgical procedures, the mean aortic cross-clamp time was 111±29.7 min, and the mean cardiopulmonary bypass time was 153±43.9 min. For isolated BAV defects, the mean aortic cross-clamp and cardiopulmonary bypass times were 89.9 ±19.5 and respectively. During the follow-up period, no patient required mechanical aortic valve replacement. One patient required pacemaker implantation on the seventh postoperative day due to the development of a third-degree atrioventricular block. In one patient, an ischemic cerebrovascular event occurred in the early postoperative period.
Discussion: Although aortic valve neocuspidization requires experience, the application of standardized procedures allows for successful outcomes in BAV defects through the tricuspidization procedure. The tricuspidization procedure provides a more physiological structure and excellent hemodynamic performance of the aortic valve.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12045251 | PMC |
http://dx.doi.org/10.5606/tgkdc.dergisi.2024.msb-30 | DOI Listing |
Herz
September 2025
Department of Cardiology, Heart Center Leipzig, University of Leipzig, Strümpellstraße 39, 04289, Leipzig, Deutschland.
Since the earliest studies on transcatheter aortic valve implantation (TAVI), the heart team concept has been an integral component of treatment planning for patients with aortic valve stenosis (AS). The primary objective is to ensure patient-specific, guideline-based treatment through the structured involvement of all relevant medical disciplines. The TAVI heart team is strongly recommended with a class I indication in both European and US clinical guidelines.
View Article and Find Full Text PDFMinerva Cardiol Angiol
September 2025
Norwich Medical School, Bob Champion Research and Education, Rosalind Franklin Road, Norwich, UK -
Introduction: Whilst aortic stenosis remains the most prevalent valvular abnormality, the management of asymptomatic severe aortic stenosis remains a clinical challenge. Recently, two randomised-controlled trials (RCTs) - EVOLVED (Early Intervention in Patients With Asymptomatic Severe Aortic Stenosis and Myocardial Fibrosis) and Early TAVR (Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis) - have been published, alongside an extended follow-up from the AVATAR (Aortic Valve Replacement Versus Conservative Treatment in Asymptomatic Severe Aortic Stenosis) study.
Evidence Acquisition: In response, we conducted a systematic review of PubMed, Ovid, and Cochrane databases, identifying RCTs up to October 29, 2024, that compared early intervention with conventional management.
ASAIO J
September 2025
From the Department of Cardiac Surgery, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
We describe a modified Park's stitch technique incorporating systematic free margin alignment to achieve complete elimination of aortic regurgitation in patients with a left ventricular assist device. The technique involves a two-step approach: first, free margin alignment of all three cusps using single interrupted 6-0 polypropylene sutures placed at the nodules of Arantius to achieve precise coaptation, followed by conventional Park's stitch using mattress sutures with autologous pericardial pledgets for central closure. The alignment sutures remain in place to provide reinforcement.
View Article and Find Full Text PDFJCI Insight
September 2025
Division of Cardiovascular Medicine, Department of Medicine.
Aortic valve stenosis is a progressive and increasingly prevalent disease in older adults, with no approved pharmacologic therapies to prevent or slow its progression. Although genetic risk factors have been identified, the contribution of epigenetic regulation remains poorly understood. Here, we demonstrated that histone deacetylase 3 (HDAC3) maintains aortic valve structure by suppressing mitochondrial biogenesis and preserving extracellular matrix integrity in valvular interstitial fibroblasts.
View Article and Find Full Text PDFJTCVS Open
August 2025
Division of Cardiovascular Surgery, Department of Surgery, University of Pennsylvania, Philadelphia, Pa.
Objective: Valve selection in acute type A aortic dissection (ATAAD) requiring aortic root replacement is challenging given the clinical acuity, unknown patient preferences, risk of surgical bleeding, and limited life expectancy. We sought to identify long-term outcomes of mechanical versus bioprosthetic aortic root replacement in young patients with ATAAD.
Methods: Retrospective review of our institution's database of ATAAD was conducted to identify patients aged 65 years and younger who underwent mechanical Bentall (mech-Bentall) or bioprosthetic Bentall (bio-Bentall) for ATAAD from 2002 to 2022.